{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:21:12Z","timestamp":1787761272939,"version":"build-2784847793"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>Management of allergic eye disease is seldom straightforward and often challenging. We conducted an online survey to elicit opinions on the preferred practice pattern in the treatment of allergic eye disease.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>An online survey questionnaire was sent to all practicing ophthalmologists using social media platforms. The respondents were asked about their clinical experience and preferred treatment in various scenarios such as mild-moderate vernal keratoconjunctivitis (VKC), chronic VKC, refractory VKC, steroid responders, giant papillae, and shield ulcer. Respondents were asked about the newer molecule (alcaftadine) and reservations regarding systemic immuno-suppressants and ordering allergy tests in their practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Ninety - one participants responded to the survey. About 57.1% of ophthalmologists reported coming across more than 10 cases per week in their practice. The most common age group was 5\u201310 years (61.1%), but adult onset VKC was also reported at 41.6% (1\u20132 per month), 37.1% (3\u20135 per month), and 13.5% (more than 10 per month). The disease is perennially present (36.7%), and a mixed form has been reported by 47.8% of ophthalmologists. Dual-acting agents were preferred by 40% in mild-moderate clinical variants. Topical steroids in slow tapering dosage were preferred by 86.7% in their prescription. Tacrolimus 0.03% was preferred by 65.9% and given for at least 3 months of continuous usage by 47.6% of ophthalmologists. High-dose topical steroids were preferred for giant papillae (67.8%) and Shields ulcers (68.3%) in our survey. Supratarsal steroid injection was preferred by 50% in treating refractory VKC in our survey.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Allergic eye disease is a common yet annoying disease. The signs and symptoms can vary from subtle, innocuous forms to devastating variants affecting vision and day-to-day work. This survey aims to elicit responses from clinicians spreading across different geographical areas and compares responses based on experience in practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_1360_22","type":"journal-article","created":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T09:14:27Z","timestamp":1672910067000},"page":"80-85","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Practice patterns and opinions in the treatment of allergic eye disease: A survey among Indian ophthalmologists"],"prefix":"10.4103","volume":"71","author":[{"given":"Smruti Rekha","family":"Priyadarshini","sequence":"first","affiliation":[{"name":"Cornea and Anterior Segment Service, L.V Prasad Eye Institute, Patia, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sujata","family":"Das","sequence":"additional","affiliation":[{"name":"Cornea and Anterior Segment Service, L.V Prasad Eye Institute, Patia, Bhubaneswar, Odisha, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"R4-20240828","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ophtha.2009.11.043","article-title":"Tailored approach to the treatment of vernal keratoconjunctivitis","volume":"117","author":"Sacchetti","year":"2010","journal-title":"Ophthalmology"},{"key":"R5-20240828","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jtos.2019.08.011","article-title":"Allergic eye disease in children and adolescents seeking eye care in India:Electronic medical records driven big data analytics report II","volume":"17","author":"Das","year":"2019","journal-title":"Ocul Surf"},{"key":"R6-20240828","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/sj.eye.6700675","article-title":"Vernal keratoconjunctivitis","volume":"18","author":"Bonini","year":"2004","journal-title":"Eye (Lond)"},{"key":"R7-20240828","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/bjophthalmol-2011-301376","article-title":"Vernal keratoconjunctivitis:An update","volume":"97","author":"De Smedt","year":"2013","journal-title":"Br J Ophthalmol"},{"key":"R8-20240828","first-page":"111","article-title":"A study of 530 cases of vernal conjunctivitis from the North West Frontier Province of Pakistan","volume":"2","author":"Khan","year":"1986","journal-title":"Pak J Ophthalmol"},{"key":"R9-20240828","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s00417-007-0697-z","article-title":"Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy","author":"Uchio","year":"2008","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R10-20240828","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.survophthal.2018.12.001","article-title":"Vernal keratoconjunctivitis","volume":"64","author":"Singhal","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"R11-20240828","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1755-3768.2008.01347.x","article-title":"Vernal keratoconjunctivitis:A major review","volume":"87","author":"Kumar","year":"2009","journal-title":"Acta Ophthalmol (Copenh)"},{"key":"R12-20240828","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.ajo.2012.11.018","article-title":"Vernal keratoconjunctivitis-like disease in adults","volume":"155","author":"Leonardi","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R13-20240828","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0161-6420(00)00092-0","article-title":"Vernal keratoconjunctivitis revisited:A case series of 195 patients with long-term followup","volume":"107","author":"Bonini","year":"2000","journal-title":"Ophthalmology"},{"key":"R14-20240828","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4103\/0301-4738.119431","article-title":"Demographic and clinical profile of vernal keratoconjunctivitis at a tertiary eye care center in India","volume":"61","author":"Saboo","year":"2013","journal-title":"Indian J Ophthalmol"},{"key":"R15-20240828","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1097\/ACI.0b013e3282efb726","article-title":"Clinical grading of vernal keratoconjunctivitis","volume":"7","author":"Bonini","year":"2007","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R16-20240828","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0301-4738.179727","article-title":"Systematic approach to managing vernal keratoconjunctivitis in clinical practice:Severity grading system and a treatment algorithm","volume":"64","author":"Gokhale","year":"2016","journal-title":"Indian J Ophthalmol"},{"key":"R17-20240828","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2332\/allergolint.09-OA-0100","article-title":"Evaluation of novel scoring system named 5-5-5 exacerbation grading scale for allergic conjunctivitis disease","volume":"58","author":"Shoji","year":"2009","journal-title":"Allergol Int"},{"key":"R18-20240828","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/archopht.117.5.643","article-title":"Inhibition of histamine-induced human conjunctival epithelial cell responses by ocular allergy drugs","volume":"117","author":"Yanni","year":"1999","journal-title":"Arch Ophthalmol"},{"key":"R19-20240828","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1590\/S0004-27492006000600013","article-title":"[Comparative study between 0.025% ketotifen fumarate and 0.1% olopatadine hydrochloride in the treatment of vernal keratoconjunctivitis","volume":"69","author":"Hida","year":"2006","journal-title":"Arq Bras Oftalmol"},{"key":"R20-20240828","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/S0161-6420(00)00538-8","article-title":"Keratitis, ulceration, and perforation associated with topical nonsteroidal anti-inflammatory drugs","volume":"108","author":"Guidera","year":"2001","journal-title":"Ophthalmology"},{"key":"R21-20240828","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1136\/bjo.2007.122044","article-title":"Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis","volume":"91","author":"Mantelli","year":"2007","journal-title":"Br J Ophthalmol"},{"key":"R22-20240828","doi-asserted-by":"crossref","first-page":"455","DOI":"10.17219\/acem\/37145","article-title":"Topical cyclosporine a 0.05% eyedrops in the treatment of vernal keratoconjunctivitis-randomized placebo-controlled trial","volume":"23","author":"Keklikci","year":"2014","journal-title":"Adv Clin Exp Med"},{"key":"R23-20240828","doi-asserted-by":"crossref","first-page":"220","DOI":"10.4103\/0301-4738.95878","article-title":"Oral cyclosporine therapy for refractory severe vernal keratoconjunctivitis","volume":"60","author":"Gokhale","year":"2012","journal-title":"Indian J Ophthalmol"},{"key":"R24-20240828","doi-asserted-by":"crossref","first-page":"507","DOI":"10.11622\/smedj.2015161","article-title":"Efficacy and safety of topical cyclosporine 1429 A 0.05% in vernal keratoconjunctivitis","volume":"57","author":"Y\u00fccel","year":"2016","journal-title":"Singapore Med J"},{"key":"R25-20240828","first-page":"872","article-title":"Topical 0.005% tacrolimus eye drop for refractory vernal keratoconjunctivitis","volume":"25","author":"Kheirkhah","year":"2011","journal-title":"Eye Lond Engl"},{"key":"R26-20240828","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2147\/OPTH.S99157","article-title":"Efficacy and safety of low-dose topical tacrolimus in vernal keratoconjunctivitis","volume":"10","author":"Shoughy","year":"2016","journal-title":"Clin Ophthalmol Auckl NZ"},{"key":"R27-20240828","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1097\/ICO.0000000000000918","article-title":"Tacrolimus in corticosteroid-refractory vernal keratoconjunctivitis","volume":"35","author":"Chatterjee","year":"2016","journal-title":"Cornea"},{"key":"R28-20240828","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1046\/j.1365-2222.2003.01538.x","article-title":"Atopy and serum eosinophil cationic protein in 110 white children with vernal keratoconjunctivitis:differences between tarsal and limbal forms","volume":"33","author":"Pucci","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"R29-20240828","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2147\/OPTH.S32936","article-title":"Steroid-induced ocular hypertension in Asian children with severe vernal keratoconjunctivitis","volume":"6","author":"Ang","year":"2012","journal-title":"Clin Ophthalmol"},{"key":"R30-20240828","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1136\/bjo.2009.165548","article-title":"Intravenous immunoglobulin (IVIg) in the management of severe refractory vernal keratoconjunctivitis","volume":"94","author":"Derriman","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R31-20240828","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s40123-016-0074-2","article-title":"Omalizumab in severe refractory vernal keratoconjunctivitis in children:Case series and review of the literature","volume":"6","author":"Doan","year":"2017","journal-title":"Ophthalmol Ther"},{"key":"R32-20240828","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1001\/jamaophthalmol.2015.5679","article-title":"Omalizumab treatment of vernal keratoconjunctivitis","volume":"134","author":"Heffler","year":"2016","journal-title":"JAMA Ophthalmol"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1360_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:30:31Z","timestamp":1787758231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijo.IJO_1360_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_1360_22","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]},"assertion":[{"value":"2022-06-03","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-10-10","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}